Business
Appointment of Independent Non-Executive Director
Appointment of Independent Non-Executive Director.
About this update from Physiomics Plc
[{"type":"text","content":"\n \n \n \n 1 September 2022\n \n \n \n \n \n \n Physiomics plc\n \n \n (\"Physiomics\") or (\"the Company\")\n \n \n \n \n \n \n \n \n Physiomics appoints new Independent Non-Executive Director\n \n \n \n \n \n \n Physiomics plc (AIM: PYC),\n the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions,\n is pleased to announce that Mr Shalabh Kumar has joined the Company's board as an Independent Non-Executive Director with immediate effect.\n \n \n Mr Shalabh Kumar is a proven business executive with over 30 years of experience within the life sciences consulting and services industry. Shalabh co-founded, and subsequently was the Chief Executive Officer of Kinapse, a life sciences consulting and outsourcing service provider, which was later acquired by Syneos Health®(Nasdaq: SYNH) after growing to employ over 600 people across UK, India and US. Prior to that, he worked for Accenture, Gillette (Procter & Gamble) and Unilever. More recently, Shalabh has been working as an independent strategy consultant and angel investor in the life sciences industry, working with biopharmaceutical companies, life sciences services and technology companies and private equity firms. Mr Kumar's recent roles include Chairman of the Board of Clustermarket Ltd, a lab software start-up; independent strategy consultant to the life sciences R&D group of Accenture plc (NYSE: ACN); and Global Head of Services at Navitas Life Sciences, a technology-backed life sciences contract research organisation.\n \n \n \n Dr Jim Millen, CEO, commented\n \n : \"On behalf of the board of Physiomics, we are delighted that Shalabh has agreed to join the Company as an Independent Non-Executive Director. Shalabh has impressive business acumen within the life sciences sector and has overseen the successful implementation of growth strategies at a number of companies. We look forward to working alongside Shalabh in the future and welcome the insight he can provide to Physiomics.\"\n \n \n Further information on Shalabh Kumar's appointment:\n The following details in relation to the appointment of Mr Shalabh Kumar are disclosed in accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules:\n Shalabh Kumar (aged 55) has held the following directorships in the past five years....